azithromycin or doxycycline for the treatment of rectal chlamydia. We investigated treatment efficacy of two treatments for rectal chlamydial infection. Method A retrospective cohort of male and female patients diagnosed with rectal chlamydial infection between 2009 and 2015 was created at the STI services (Clinic 275) in Adelaide, Australia. Patients were included in the analysis if they were treated with azithromycin (1 g single dose) or doxycycline (100 mg twice a day for 10 days) and returned for repeat testing 14 to 180 days after treatment commenced. Log binomial models were used to estimate the relative risk (RR) of recurrent rectal chlamydia associated with the treatment with azithromycin versus doxycycline. Results Of 526 patients diagnosed with rectal chlamydial infections over the study period, 73% (n=384) were men and 27% (n=142) were women; 419 (79.7%), 93 (17.7%) and 14 (2.6%) patients were treated with doxycycline, azithromycin or other medication respectively. Of these patients, 173 (41.3%) of 419 doxycycline-treated patients and 31 (33.3%) of 93 azithromycin-treated patients were retested between 14 and 180 days after treatment commenced (p=0.16). Among these patients, the repeat rectal chlamydia test was less commonly positive in those treated with doxycycline (5.8%; 95% Confidence Interval (CI) 0.03-0.10) compared with those treated with azithromycin (19.4%; 95% CI 0.09-0.36) and (p=0.01). In the multivariate analysis, azithromycin-treated patients had a significant higher risk of a positive test in the 14 and 180 days after treatment commenced (adjusted relative risk (aRR) 2.78, 95% CI 1.10-7.05). Conclusion The findings suggest that doxycycline may be more effective than azithromycin in treating rectal chlamydial infection.
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LYMPHOGRANULOMA 88% 2006-2013% to 68% 2014-2015 Introduction Behavioural surveys can provide insight into the attitudes and context associated with risk of sexually transmitted infections (STIs), but interpretation is hampered by theirreliance on self-reported STI history rather than confirmed diagnoses. We aimed to determine the feasibility and acceptability of linking clinic patients' online survey data on STI risk factors with the national surveillance dataset on STI diagnoses (GUMCADv2), which contains electronic patient record (EPR) data routinely submitted to Public Health England by sexual health clinics. Methods Between May and September 2016, attendeesat 16 sexual health clinicsacross Englandwereinvited to completean onlinesurveyon knowledge, attitudes, and behaviours around STI risk, using a clinic tablet or personal device (e.g. smartphone). Participants were given a unique study identifier (ID) to type into the survey, and provided consent to participate and to data linkage. Screening questions routed eligible participants, !15 years old and sexually active in the past year, to the full survey. Recruiting clinic staff kept record of study IDs and corresponding patient IDs. We linked surveysto GUMCADv2 with deterministic and probabilistic methods, using the recorded ID numbers as well as age, gender, and clinic attendance date. We examined recruitment and linkage success for a target of 7500 eligible attendees, and used univariable logistic regression and Z-test for proportions to assess selection bias. Results 6283 clinic attendees agreed to take part in the study, of whom73.6% (4626) completed the survey. 95.9% (4437) of survey respondents were eligible; 59.2% of our recruitment target. Survey completionamong those agreeing to participate was higher in the 9 clinics that recruited !50% of their target than those that did not (84.9% vs 53.0%). Survey completion was also higher in those who agreed to fill in the survey in clinic than in those who agreed to do soat home (87.3% vs 
